Business Context and Reporting Period
This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on February 6, 2013, covering events occurring on January 31, 2013. The filing discloses the entry into a material definitive agreement involving a revolving credit facility and the issuance of unregistered equity securities.
Key Financial Metrics and Obligations
- Debt Facility: Entered into a Multiple Advance Revolving Credit Note with Plato and Associates, LLC.
- Maximum Principal: $10 million.
- Interest Rate: 6% per annum (Stated Interest Rate).
- Default Interest Rate: 14% per annum (Stated Rate + 8%).
- Repayment Terms: Interest payable quarterly starting April 10, 2013; principal and accrued interest due February 24, 2014.
- Equity Issuance: Issued a warrant to purchase 1,250,000 shares of common stock.
- Warrant Terms: Exercise price of $3.20 per share; vesting date October 31, 2013; expiration date January 31, 2019.
Material Changes
The filing represents a new material financial obligation and potential equity dilution. The company has secured access to up to $10 million in revolving funding, though the text does not specify the amount drawn down as of the filing date. No prior comparable period data is provided in this specific filing as it reports a discrete event rather than periodic financial results.
Outlook, Risks, and Contingencies
- Liquidity: The agreement provides a mechanism for the company to access capital on a revolving basis to meet operational needs.
- Dilution Risk: The issuance of warrants for 1,250,000 shares creates potential future dilution for existing shareholders if exercised.
- Default Risk: Failure to comply with the Note's provisions or nonpayment of amounts due will trigger a default interest rate of 14% per annum.
- Management Commentary: The filing contains no explicit management commentary or forward-looking guidance beyond the terms of the agreement.
Investor Verification Checklist
- Verify the actual amount drawn down from the $10 million credit facility, as the filing only states the maximum principal amount.
- Review the full text of the Note (Exhibit 10.0) for specific covenants and events of default not summarized in the report.
- Assess the impact of the 1,250,000 warrant shares on the company's fully diluted share count upon vesting in October 2013.
- Confirm the company's current cash position to evaluate its ability to service the quarterly interest payments commencing April 10, 2013.